[Adjuvant drug treatment in diabetic patients undergoing percutaneous coronary intervention]

The authors describe the adjuvant drug treatment during and after percutaneous coronary intervention in order to obtain the reduction of major cardiovascular events, focusing in diabetic patients. In the clinical follow-up of diabetic patients after PCI, special attention to the control measures of cardiovascular risk factors should be observed. Among those measures, a normal glycemic level is fundamental, which can be achieved with usual clinical care. Antiplatelet therapy is a controversy issue until know. Although combined antiplatelet therapy with aspirin and a thienopyridynic is well supported by a number of clinical trials, adding GPIIb/IIIa agents as adjuvants in diabetic patients should not be irrestrictive as suggested by some authors; they should be restricted to patients with a significative thrombotic burden.